Group 1 - The company, Xuan Zhu Bio-B (02575.HK), plans to globally offer 67.33 million H-shares, with 6.73 million shares available in Hong Kong and 60.60 million shares for international offering, with the offering period from October 6 to October 10, 2025, at a price of HKD 11.60 per share [1] - The company is a China-based biopharmaceutical firm focused on innovation, with over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [2] - The company has established a comprehensive internal R&D platform since the acquisition of Shandong Xuan Zhu Pharmaceutical Technology Co., Ltd. in 2008, supporting a balanced pipeline of products [2] Group 2 - The company has entered into cornerstone investment agreements, with investors agreeing to subscribe for shares totaling HKD 76.60 million, equating to 6.60 million shares at the offering price [3] - The net proceeds from the global offering are expected to be approximately HKD 701 million, with 45% allocated for R&D of core products, 14% for key products, 11% for other candidate drugs, 20% for enhancing commercialization and marketing capabilities, and 10% for working capital and general corporate purposes [3]
轩竹生物-B(02575.HK)拟全球发售6733.35万股H股 预计10月15日上市
Ge Long Hui·2025-10-05 23:12